News
CHRS
--
0.00%
--
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation committee of the Company's board of directors granted options to purchase an aggregate of 140,500 shares of the common stock of the Company to 10 newly hired non-officer employees, with a per share exercise price of $17.92, the closing trading price on the grant date.
GlobeNewswire · 11/20 21:01
The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5)
Benzinga · 11/06 12:47
Coherus BioSciences (CHRS) Lags Q3 Earnings and Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/05 22:35
Coherus BioSciences Reports Third Quarter 2020 Financial Results
- Third Quarter UDENYCA(R) Net Sales of $113.6 Million -
GlobeNewswire · 11/05 21:06
Coherus BioSciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Coherus BioSciences, Inc. (NASDAQ:CHRS) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 5, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/05 19:47
Coherus BioSciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Coherus BioSciences, Inc.
ACCESSWIRE · 11/05 19:45
Coherus BioSciences (CHRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks · 10/29 17:34
Coherus BioSciences (CHRS) Moves to Buy: Rationale Behind the Upgrade
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Zacks · 10/26 17:00
Why Coherus BioSciences (CHRS) is Poised to Beat Earnings Estimates Again
Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks · 10/26 16:10
CHRS or ILMN: Which Is the Better Value Stock Right Now?
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Zacks · 10/26 15:40
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Ocugen (NASDAQ: OCGN) - P/E: 0.05 2. Coherus BioSciences (NASDAQ: CHRS) - P/E: 7.39 3. Oncternal Therapeutics (NASDAQ: ONCT) - P/E: 1.96 4. OpGen (NASDAQ: OPGN) - P/E: 2.94 5. Karuna Therapeutics (NASDAQ: KRTX) - P/E: 0.16Ocugen has reported Q2 earnings per share at -0.19, which has decreased by 171.43% compared to Q1, which was -0.07. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Coherus BioSciences reported earnings per share at 0.81, whereas in Q1 earnings per share sat at 0.48. Coherus BioSciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Oncternal Therapeutics saw a decrease in earnings per share from -0.31 in Q1 to -0.34 now. Oncternal Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.OpGen's earnings per share for Q2 sits at -0.49, whereas in Q1, they were at -0.43. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Karuna Therapeutics has reported Q2 earnings per share at -0.65, which has decreased by 96.97% compared to Q1, which was -0.33. Karuna Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Click here for options trades from Benzinga * 5 Value Stocks To Watch In The Real Estate Sector * Lakeland Financial: Q3 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/26 14:51
Coherus BioSciences to Report Third Quarter Financial Results on November 5th
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update. After releasing third quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com.Conference Call InformationWhen: Thursday, November 5, 2020 starting at 4:30 p.m. ESTWebcast: https://investors.coherus.comDial-in: 844-452-6826 (Toll-Free U.S. and Canada) or 765-507-2587 (International) Please dial-in 15 minutes early to ensure a timely connection to the call.Conference ID: 7079429About Coherus BioSciences, Inc.Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the United States and is advancing additional product candidates including CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ranibizumab) biosimilar, Innovent’s Avastin® (bevacizumab) biosimilar towards commercialization, as well as CHS-2020, an Eylea® (aflibercept) biosimilar. For additional information, please visit www.coherus.com. ContactDavid S. Arrington Investor Relations & Corporate Affairs Coherus BioSciences, Inc. darrington@coherus.com +1 (650) 395-0196
GlobeNewswire · 10/22 21:15
Coherus BioSciences to Report Third Quarter Financial Results on November 5th
Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus' management team will host a conference call to discuss financial results and provide a general business update.
GlobeNewswire · 10/22 20:24
Healthcare: XLV Survey For October
A dashboard with metrics in healthcare industries.Value and quality scores, and their evolution since last month.A list of cheap stocks.
Seekingalpha · 10/18 19:46
Report [2020-2026] Oncology Biosimilars Market Size, Share, Trends, Growth, Analysis, Competitive Landscape, Revenue, Forecast
The global Oncology Biosimilars Market is poised for rapid growth as patents of expensive biologic drugs are on the verge of expiration.
GlobeNewswire · 10/14 11:56
5 Value Stocks To Watch In The Healthcare Sector
Benzinga · 10/05 13:44
Hedge Funds Are Selling Coherus Biosciences Inc (CHRS)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/28 22:23
Our View On Coherus BioSciences' (NASDAQ:CHRS) CEO Pay
Denny Lanfear has been the CEO of Coherus BioSciences, Inc. (NASDAQ:CHRS) since 2010, and this article will examine...
Simply Wall St. · 09/13 15:10
Coherus Neulasta biosimilar loses preferred status at Express Scripts
Coherus BioSciences ([[CHRS]] -2.6%) slips on below-average volume in apparent reaction to the exclusion of Udencya (pegfilgrastim-cbqv), a biosimilar to Amgen's ([[AMGN]] -0.8%) Neulasta, from Express Scripts' 2021 preferred formulary
Seekingalpha · 08/20 19:28
Coherus Bioscien Rises 15.74% on Heavy Volume: Watch For Potential Pullback
Coherus Bioscien (NASDAQ:CHRS) traded in a range yesterday that spanned from a low of $18.47 to a high of $20.55. Yesterday, the shares gained 15.7%, which took the trading range above the 3-day high of $18.35 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 08/07 17:26
Webull provides a variety of real-time CHRS stock news. You can receive the latest news about Coherus through multiple platforms. This information may help you make smarter investment decisions.
About CHRS
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
More